Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation
Muchaala Yeboah, Charys Papagregoriou, Des C. Jones, H.T. Claude Chan, Guangan Hu, Justine S. McPartlan, Torbjörn Schiött, Ulrika Mattson, C. Ian Mockridge, Ulla-Carin Tornberg, Björn Hambe, Anne Ljungars, Mikael Mattsson, Ivo Tews, Martin J. Glennie, Stephen M. Thirdborough, John Trowsdale, Björn Frendeus, Jianzhu Chen, Mark S. Cragg, Ali Roghanian
Muchaala Yeboah, Charys Papagregoriou, Des C. Jones, H.T. Claude Chan, Guangan Hu, Justine S. McPartlan, Torbjörn Schiött, Ulrika Mattson, C. Ian Mockridge, Ulla-Carin Tornberg, Björn Hambe, Anne Ljungars, Mikael Mattsson, Ivo Tews, Martin J. Glennie, Stephen M. Thirdborough, John Trowsdale, Björn Frendeus, Jianzhu Chen, Mark S. Cragg, Ali Roghanian
View: Text | PDF
Research Article Immunology

LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation

  • Text
  • PDF
Abstract

Despite advances in identifying the key immunoregulatory roles of many of the human leukocyte immunoglobulin-like receptor (LILR) family members, the function of the inhibitory molecule LILRB3 (ILT5, CD85a, LIR3) remains unclear. Studies indicate a predominant myeloid expression; however, high homology within the LILR family and a relative paucity of reagents have hindered progress toward identifying the function of this receptor. To investigate its function and potential immunomodulatory capacity, a panel of LILRB3-specific monoclonal antibodies (mAbs) was generated. LILRB3-specific mAbs bound to discrete epitopes in Ig-like domain 2 or 4. LILRB3 ligation on primary human monocytes by an agonistic mAb resulted in phenotypic and functional changes, leading to potent inhibition of immune responses in vitro, including significant reduction in T cell proliferation. Importantly, agonizing LILRB3 in humanized mice induced tolerance and permitted efficient engraftment of allogeneic cells. Our findings reveal powerful immunosuppressive functions of LILRB3 and identify it as an important myeloid checkpoint receptor.

Authors

Muchaala Yeboah, Charys Papagregoriou, Des C. Jones, H.T. Claude Chan, Guangan Hu, Justine S. McPartlan, Torbjörn Schiött, Ulrika Mattson, C. Ian Mockridge, Ulla-Carin Tornberg, Björn Hambe, Anne Ljungars, Mikael Mattsson, Ivo Tews, Martin J. Glennie, Stephen M. Thirdborough, John Trowsdale, Björn Frendeus, Jianzhu Chen, Mark S. Cragg, Ali Roghanian

×

Figure 3

LILRB3 ligation regulates T cell activation and proliferation.

Options: View larger image (or click on image) Download as PowerPoint
LILRB3 ligation regulates T cell activation and proliferation.
CFSE-labe...
CFSE-labeled PBMCs were stimulated with antibodies against human CD3 (0.02 μg/mL) and CD28 (5 μg/mL) in the presence or absence of isotype control (iso ctrl) or LILRB3 mAb (10 μg/mL) and proliferation measured through CFSE dilution after 3–5 days. (A) LILRB3 mAbs were deglycosylated (Degly) through PNGase treatment, as confirmed by SDS-PAGE; representative clone A1 shown. (B) Assessing T cell activation and proliferation following treatment. Light microscopy images following PBMC stimulation in culture. CD8+ T cell proliferation was assessed through CFSE dilution; plots and images from a donor with profound A1-induced inhibition shown, histograms (% proliferation indicated) and microscopy images shown (original magnification, ×10). (C) Assessing the effects of deglycosylated LILRB3 mAbs on T cell proliferation. CFSE dilution of CD8+ T cells, treated with the representative LILRB3 mAb, was assessed by flow cytometry. Data normalized to anti-CD3/CD28–treated samples and mean represented by solid bars. One-way ANOVA performed (**P < 0.005; ***P < 0.0005); n = 13–20 independent donors (each color represents an individual donor).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts